161 related articles for article (PubMed ID: 38506974)
1. Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer.
Yang Z; Shao Y; Huang H; Liu Y; Wang Z; Wang Y
World J Urol; 2024 Mar; 42(1):171. PubMed ID: 38506974
[TBL] [Abstract][Full Text] [Related]
2. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
Uemura H; Koroki Y; Iwaki Y; Imanaka K; Kambara T; Lopez-Gitlitz A; Smith A; Uemura H
BMC Urol; 2020 Sep; 20(1):139. PubMed ID: 32878613
[TBL] [Abstract][Full Text] [Related]
3. Real-world analysis of apalutamide-associated skin adverse events in Japanese patients with advanced prostate cancer: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y; Kato T; Fukuhara H; Kobayashi K; Ohira S; Ikeda K; Daizumoto K; Katayama S; Shimizu R; Nishimura K; Nagami T; Hayashida Y; Hirama H; Takamoto A; Dainichi T; Sugimoto M;
Int J Clin Oncol; 2022 Aug; 27(8):1348-1355. PubMed ID: 35596089
[TBL] [Abstract][Full Text] [Related]
4. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
[TBL] [Abstract][Full Text] [Related]
5. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
6. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; Lopez-Gitlitz A; Trudel GC; Espina BM; Shu Y; Park YC; Rackoff WR; Yu MK; Small EJ;
N Engl J Med; 2018 Apr; 378(15):1408-1418. PubMed ID: 29420164
[TBL] [Abstract][Full Text] [Related]
7. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
8. Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
Hussain A; Jiang S; Varghese D; Appukkuttan S; Kebede N; Gnanasakthy K; Macahilig C; Waldeck R; Corman S
BMC Cancer; 2022 Mar; 22(1):304. PubMed ID: 35317768
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
10. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
T'jollyn H; Ackaert O; Chien C; Lopez-Gitlitz A; McCarthy S; Ruixo CP; Karsh L; Chi K; Chowdhury S; Ruixo JP; Agarwal N
Cancer Chemother Pharmacol; 2022 May; 89(5):629-641. PubMed ID: 35366072
[TBL] [Abstract][Full Text] [Related]
12. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
[TBL] [Abstract][Full Text] [Related]
13. Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.
Chung BH; Huang J; Ye ZQ; He DL; Uemura H; Arai G; Kim CS; Zhang YY; Koroki Y; Jeong S; Mundle S; Triantos S; McCarthy S; Chi KN; Ye DW
Asian J Androl; 2022; 24(2):161-166. PubMed ID: 34259202
[TBL] [Abstract][Full Text] [Related]
14. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
15. Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide.
Bivins VM; Durkin M; Khilfeh I; Rossi C; Kinkead F; Waters D; Lefebvre P; Pilon D; Ellis L
Future Oncol; 2022 Oct; 18(32):3595-3607. PubMed ID: 36196743
[No Abstract] [Full Text] [Related]
16. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
Uemura H; Arai G; Uemura H; Suzuki H; Iijima K; Nishimura K; Fujii K; Hatayama T; Aoyama J; Deprince K; Lopez-Gitlitz A; McCarthy S; Larsen JS; Li J; Chi KN
Int J Urol; 2021 Mar; 28(3):280-287. PubMed ID: 33295007
[TBL] [Abstract][Full Text] [Related]
17. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
Small EJ; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; De Porre P; Smith AA; Zhang K; Lopez-Gitlitz A; Smith MR
Ann Oncol; 2019 Nov; 30(11):1813-1820. PubMed ID: 31560066
[TBL] [Abstract][Full Text] [Related]
19. Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
Tohi Y; Kato T; Kobayashi K; Daizumoto K; Fukuhara H; Ohira S; Katayama S; Shimizu R; Takamoto A; Nishimura K; Ikeda K; Nagami T; Hayashida Y; Hirama H; Naito H; Tomida R; Sasaki Y; Yamamoto S; Shimizu S; Sugimoto M;
Jpn J Clin Oncol; 2024 Feb; 54(2):167-174. PubMed ID: 37840362
[TBL] [Abstract][Full Text] [Related]
20. Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer.
Cremante M; Puglisi S; Gandini A; Guadagno A; Catalano F; Damassi A; Murianni V; Llaja Obispo MA; Banna GL; Buti S; Rebuzzi SE; Rescigno P; Fornarini G
J Oncol Pharm Pract; 2023 Oct; 29(7):1748-1753. PubMed ID: 37282554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
